A. Scheed
Medical University of Vienna
18 Papers
74 Citations
A. Scheed is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Lung transplantation & Medicine. The author has an hindex of 10, co-authored 18 publications. Previous affiliations of A. Scheed include University of Vienna.
Chat about Author
Papers
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
Rajkumar Savai,Soni Savai Pullamsetti,Julia Kolbe,Ewa Bieniek,Robert Voswinckel,Ludger Fink,A. Scheed,Christin Ritter,Bhola K. Dahal,Axel Vater,Sven Klussmann,Hossein Ardeschir Ghofrani,Norbert Weissmann,Walter Klepetko,Gamal Andre Banat,Werner Seeger,Friedrich Grimminger,Ralph T. Schermuly +17 more
TL;DR: In this article, the number and cross-sectional distribution of inflammatory cells in different sizes of pulmonary arteries from explanted lungs of patients with idiopathic pulmonary arterial hypertension versus healthy donor lungs were evaluated.
372
Clinical Ex Vivo Lung Perfusion—Pushing the Limits
Clemens Aigner,Alexis Slama,K. Hötzenecker,A. Scheed,B. Urbanek,W. Schmid,F. J. Nierscher,György Lang,Walter Klepetko +8 more
TL;DR: This paper summarizes the results of a prospective study of lung transplantation using only initially unacceptable donor lungs, which were improved by EVLP for 2–4 h, and has a significant potential to improve the quality of otherwiseacceptable donor lungs.
188
A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation
Peter Jaksch,A. Scheed,M. Keplinger,Mai-Britt Ernst,Theresa Dani,Ulrike Just,Hesam Nahavandi,Walter Klepetko,Robert Knobler +8 more
TL;DR: It is suggested that early use of ECP could be an effective adjunct treatment for patients who develop BOS after lung transplantation and compared with BOS patients not treated with ECP, the ECP responders showed an improved graft survival (p = 0.05).
128
Alemtuzumab in Lung Transplantation: An Open‐Label, Randomized, Prospective Single Center Study
TL;DR: This novel therapeutic agent had no impact on survival, infections rates, kidney function, infectious complications and posttransplant lymphoproliferative disorder.
46
Prospective Analysis of Human Cytomegalovirus DNAemia and Specific CD8+ T Cell Responses in Lung Transplant Recipients
Lukas Weseslindtner,Heidrun Kerschner,D. Steinacher,Raffael Nachbagauer,Michael Kundi,Peter Jaksch,Benedikt Simon,L. Hatos-Agyi,A. Scheed,Walter Klepetko,Elisabeth Puchhammer-Stöckl +10 more
TL;DR: The data indicate that HCMV‐specific CD8+ T cells influence the magnitude of H CMV DNAemia episodes, and it is proposed that a standardized measurement of CD8 + T cell immunity might contribute to monitoring the immune status of LuTRs posttransplantation.
43